Progesterone Therapy Increases Free Thyroxine Levels—Data from a Randomized Placebo-Controlled 12-Week Hot flush Trial
Clinical Endocrinology (2013) 79, 282–287 doi: 10.1111/cen.12128 ORIGINAL ARTICLE Progesterone therapy increases free thyroxine levels—data from a randomized placebo-controlled 12-week hot flush trial P. Sathi*, S. Kalyan†,‡, C. L. Hitchcock*, M. Pudek¶ and J. C. Prior*,§ *Centre for Menstrual Cycle and Ovulation Research, Endocrinology/Medicine, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, †Centre for Menstrual Cycle and Ovulation Research, Endocrinology/Medicine, University of British Columbia, Vancouver, BC, Canada, ‡Alexander von Humboldt Research Fellow in Immunology, University- Hospital Schleswig-Holstein, Christian-Albrechts University Kiel, Germany, §School of Population and Public Health, University of British Columbia and Vancouver Coastal Health Research Institute and ¶Pathology, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, Canada (Received 10 October 2012; returned for revision 2 November Summary 2012; finally revised 29 November 2012; accepted 10 December 2012) Objective Thyroid hormones and progesterone both influence core temperature, metabolism and are crucial during pregnancy. Our objective was to discover whether progesterone therapy caused changes in thyroid physiology compared with placebo. Introduction Design Post hoc analysis from a randomized (1:1) placebo-controlled 12-week trial of oral micronized progesterone (Progesterone, 300 mg/ Women are more likely than men (P < 0.0001) to experience d at bedtime) for hot flushes (vasomotor symptoms, VMS) conducted clinical thyroid problems.1,2 The prevalence of TSH abnormali- in an academic medical centre. ties increases with increasing age2,3 and with lower socioeco- Patients Postmenopausal euthyroid, healthy (without cardio- nomic status2; increasing age and lower socioeconomic status vascular diseases or risks) women, 1–11 years since last flow on are also related to decreased progesterone production.4 The no thyroid or ovarian hormone therapy with VMS participated.
[Show full text]